Global Endowment Management LP Boosts Holdings in Humana Inc. (NYSE:HUM)

Global Endowment Management LP lifted its stake in shares of Humana Inc. (NYSE:HUM) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,827 shares of the insurance provider’s stock after purchasing an additional 131 shares during the period. Global Endowment Management LP’s holdings in Humana were worth $464,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. FPC Investment Advisory Inc. purchased a new stake in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA raised its stake in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management purchased a new position in Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. boosted its stake in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Down 0.5 %

HUM opened at $285.48 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $34.46 billion, a P/E ratio of 28.69, a P/E/G ratio of 2.05 and a beta of 0.62. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The business has a fifty day simple moving average of $265.80 and a 200-day simple moving average of $270.33.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analysts Set New Price Targets

HUM has been the topic of several research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Guggenheim initiated coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price on the stock. Barclays upped their price target on Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research report on Friday, April 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Morgan Stanley dropped their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Humana has an average rating of “Hold” and an average target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.